Abstract: The present invention concerns a tryptophan metabolite chosen from kynurenic acid, anthranilic acid, quinolinic acid, picolinic acid, quinaldic acid and the mixtures of same or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt of same, for use as a drug intended for increasing and/or maintaining muscle mass and/or strength in a mammal, and in particular intended for treating and/or preventing muscle atrophy in mammals and/or for promoting muscle growth in mammals doing exercise and aiming to increase muscle mass and/or quality and/or strength, for preventing the appearance of symptoms of sarcopenia or for rehabilitation following muscle loss and/or for improving recovery time after an intense physical effort.
Type:
Grant
Filed:
September 5, 2017
Date of Patent:
June 28, 2022
Assignee:
METABRAIN RESEARCH
Inventors:
Sophie N. Raynal, Annick Audet, Valérie Autier, Christine Charon, Jean-Denis Durand, Micheline Kergoat
Abstract: The present invention concerns a tryptophan metabolite chosen from kynurenic acid, anthranilic acid, quinolinic acid, picolinic acid, quinaldic acid and the mixtures of same or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt of same, for use as a drug intended for increasing and/or maintaining muscle mass and/or strength in a mammal, and in particular intended for treating and/or preventing muscle atrophy in mammals and/or for promoting muscle growth in mammals doing exercise and aiming to increase muscle mass and/or quality and/or strength, for preventing the appearance of symptoms of sarcopenia or for rehabilitation following muscle loss and/or for improving recovery time after an intense physical effort.
Type:
Application
Filed:
September 5, 2017
Publication date:
August 15, 2019
Applicant:
METABRAIN RESEARCH
Inventors:
Sophie N. Raynal, Annick Audet, Valérie Autier, Christine Charon, Jean-Denis Durand, Micheline Kergoat
Abstract: This invention relates to oxime and alkoxy derivatives of the general formula (I), or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and/or prevention of muscle atrophy in mammals and/or for limiting muscular atrophy in mammals and/or to promote muscle growth in exercising mammals aimed at increasing muscle mass and quality, preventing the occurrence of symptoms of sarcopenia related to age or rehabilitation after a muscle loss, age-related muscle atrophy and/or the consequences of drug therapy and/or immobilization and/or cachexia.
Type:
Grant
Filed:
April 14, 2016
Date of Patent:
July 16, 2019
Assignee:
METABRAIN RESEARCH
Inventors:
Sophie N. Raynal, Micheline R. Kergoat, Valerie Autier, Christine G. Charon, Jean-Denis Durand, Franck F. Lepifre, Annick M. Audet
Abstract: The present invention relates to a thiophene derivative of the following general formula I or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof or to its use as a drug in particular intended for treating and/or preventing diabetes, its complications and/or associated pathologies, advantageously diabetes of type II and hyperglycemia.
Type:
Grant
Filed:
July 16, 2013
Date of Patent:
October 3, 2017
Assignee:
METABRAIN RESEARCH
Inventors:
Franck F. Lepifre, Gersande R. Lena, Valerie Autier, Micheline R. Kergoat, Lauren R. Faveriel, Christine G. Charon, Sophie N. Raynal, Annick M. Audet
Abstract: The present invention relates to imidazopyridine derivatives of the following general formula I: and to their use as a drug, in particular in treating and/or preventing diabetes, its complications and/or associated pathologies.
Type:
Grant
Filed:
July 16, 2013
Date of Patent:
July 5, 2016
Assignee:
METABRAIN RESEARCH
Inventors:
Franck F. Lepifre, Gersande R. Lena, Valerie Autier, Micheline R. Kergoat, Christine G. Charon, Sophie N. Raynal, Annick M. Audet